The new update to the 2009 American Society of Clinical Oncology (ASCO) guideline on the pharmacologic interventions for breast cancer risk reduction now lists aromatase inhibitor exemestane (Aromasin, Pfizer) as an option for postmenopausal women for primary risk reduction that are at an increased risk of developing invasive breast cancer.
Estimates of the cost of fraud in the Medicare system range broadly from $17 billion to $90 billion. However, there are no estimates of-or methods to detect-how much of the wasted money is attributable to old-fashioned human error rather than blatant crime.
Complete response, priority review, fast track
Blood pressure (BP) response to changes in dietary sodium and potassium is reproducible over the long term and may help identify potential candidates at risk for hypertension and cardiovascular disease, according to a study published in the journal Hypertension.
Long-term use of calcium-channel blockers (CCBs) may increase the risk of breast cancer in postmenopausal women, but additional research is needed to confirm, according to a study in JAMA Internal Medicine, published online August 5.
There's more political pressure on governors to contain costs and influence healthcare delivery. An industry think tank aims to tackle cost and quality for state leaders.
When a Harvard professor recants her research on ROI, you know wellness programs are doomed
Oral oncolytics are relatively new to the field of cancer therapy. However, they now make up about 25% of the oncology market and their use is continually expanding. The current insurance system is not efficiently equipped to handle their rapid entry into the market.
Under the rule, individuals associated with security mishaps will become personally liable for their organization’s transgressions
The only predictable aspect of the influenza season is its unpredictability, according to experts.
More than a third of young people believe prescription stimulant abuse is a big problem among their peers, according to a new survey.
Approximately 90,000 Americans die every year as a result of kidney disease. This disease produces no symptoms until it is in the advanced stages, so people in the early stages are not likely to know they have it unless they are tested.
A severe decline in the use of estrogen therapy (ET) due to misunderstanding the findings of the Women’s Health Initiative (WHI) Estrogen Plus Progestin Trial has particularly affected hysterectomized women in their 50s, leading to excess mortality, according to a study published online in the American Journal of Public Health.
Meanwhile, the data collected isn't exactly in the right format for secondary use
Partners provide education and boots on the ground to improve health and attract members
Financial incentives will be linked to comprehensive care which includes the mind and body
CMS has increased the number of telehealth services it will reimburse under Medicare
State-level data shows potential cost savings when patients follow regimens
Provider relationships are essential to help patients self-manage clinical risks
MCOs are looking at each segment separately to assess opportunities for small business
Modernize delivery models and help PCPs do more now and in the future
The Comprehensive Primary Care Initiative expects high performers to up their game with technology, data sharing and quality milestones
CDC defines risk factors
WellPoint's RBP model puts market forces to work
A combination of diabetes, hypertension and dyslipidemia is the telltale sign of high risk
CoOportunity offers narrow- and tiered-network products, but don't call them HMOs
New OIG report reveals dieticians and massage therapists prescribing drugs and says plans have obligation to verify claims
Physicians have yet to master the implications of genetic test and their relationship to treatment, while plans await outcome evidence
A recent Supreme Court Decision underscores the necessity of counsel reviewing the dispute resolution terms in health plan contracts with providers
